Bank Of America Corp Ocular Therapeutix, Inc Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Bank Of America Corp holds 227,053 shares of OCUL stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

227,053

Previous 86,989 161.01%

Holding current value

$1.55 Million

Previous $387,000 433.85%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.85 - $10.93 $539,246 - $1.53 Million	140,064 Added 161.01%	227,053 $2.07 Million
Q4 2023 Feb 14, 2024	SELL	$2.08 - $4.52 $16,879 - $36,679	-8,115 Reduced 8.53%	86,989 $387,000
Q2 2023 Aug 14, 2023	BUY	$4.6 - $7.64 $130,285 - $216,387	28,323 Added 42.41%	95,104 $490,000
Q1 2023 May 12, 2023	SELL	$2.79 - $6.27 $87,128 - $195,805	-31,229 Reduced 31.86%	66,781 $351,000
Q4 2022 Feb 10, 2023	BUY	$2.61 - $4.41 $104,334 - $176,289	39,975 Added 68.88%	98,010 $275,000

Q3 2022 Nov 14, 2022	BUY	$4.09 - $6.5 $76,581 - $121,706	18,724 Added 47.63%	58,035 $240,000
Q2 2022 Aug 12, 2022	SELL	$3.01 - $5.22 $30,882 - $53,557	-10,260 Reduced 20.7%	39,311 $158,000
Q1 2022 May 16, 2022	SELL	$4.83 - $7.35 $161,978 - $246,489	-33,536 Reduced 40.35%	49,571 $246,000
Q4 2021 Feb 08, 2022	BUY	$6.16 - $12.07 $187,652 - $367,688	30,463 Added 57.87%	83,107 $579,000
Q3 2021 Nov 15, 2021	BUY	$9.7 - $14.34 $161,078 - $238,130	16,606 Added 46.08%	52,644 $526,000
Q2 2021 Sep 13, 2021	BUY	$13.43 - $19.16 $483,990 - $690,488	36,038 New	36,038 $511,000

Others Institutions Holding OCUL

# of Institutions

148

Shares Held

123M

Call Options Held

185K

Put Options Held

507K

View Full List

About OCULAR THERAPEUTIX, INC

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $526M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

More about OCUL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Ocular Therapeutix, Inc Transaction History